|Over a month ago|
Four new option listings on August 24th » 08:3008/2408/24/22
APGN, RXST, UGRO
New option listings for…
New option listings for August 24th include APE Stock (APE), Apexigen Inc (APGN), RxSight Inc (RXST), and Urban Gro Inc (UGRO).
RxSight files $200M mixed securities shelf 16:3708/0808/08/22
RxSight raises FY22 revenue view to $44M-$46M from $41.5M-$45.5M » 16:2308/0808/08/22
FY22 revenue consensus…
FY22 revenue consensus $43.97M. The revised guidance range implies an annual growth rate versus 2021 of 95% to 104%. The company has increased its 2022 gross margin guidance range to 37% to 38% of revenue, up from the previous range of 35% to 36% of revenue. The Company also narrowed its operating expense guidance to a range of $88.0 million to $90.0 million compared to prior guidance of $86.0 million to $90.0 million.
RxSight reports Q2 EPS adjusted EPS (50c) vs ($3.24) last year » 16:2208/0808/08/22
Reports Q2 revenue…
Reports Q2 revenue $11.36M, consensus $10.75M. "In the second quarter of 2022, RxSight continued to establish a track record of strong year-over-year and sequential growth, driven by vigorous demand for our LDD and accelerating utilization of our LAL," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. "Our progress thus far reflects the powerful benefits doctors and patients derive when they choose our unique LAL system, enabling them to achieve excellent vision without glasses or compromises."
RxSight announces $50M 'at-the-market' equity offering program » 16:1408/0808/08/22
RxSight announced that it…
RxSight announced that it has filed a $200M shelf registration statement with the SEC. Once declared effective by the SEC, the shelf registration statement would permit the company to sell, from time to time, up to $200M in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the company with flexibility to access additional capital when market conditions are appropriate. As part of the shelf registration, the company also filed a prospectus supplement to sell, of the $200M of securities being registered, up to an aggregate of $50M of its common stock through an "at-the-market" offering. The shares will be offered through BofA Securities as sales agent. The registration statement has been filed with the SEC, but has not yet become effective.
|Over a quarter ago|
RxSight sees 2022 revenue $41.5M-$45.5M vs. prior $40M-$44M » 16:3305/0505/05/22
Consensus $42.26M. The…
Consensus $42.26M. The company did not change its guidance for 2022 gross margin or operating expenses, which are ranges of 35% to 36% of revenue, and $86M to $90M, respectively.
RxSight reports Q1 EPS (64c), consensus (65c) » 16:3205/0505/05/22
Reports Q1 revenue $8.9M,…
Reports Q1 revenue $8.9M, consensus $7.32M. The company said, "We are very pleased with our strong start to 2022. Solid revenue growth, driven by an expanding installed base and rising procedure volumes, confirms that an increasing number of doctors and patients are selecting our premium cataract solution for the significant advantages it provides. We are confident in our ability to execute our growth strategy in 2022 and beyond by continuing to focus on our core strengths: exceptional visual outcomes across a range of patient types and preferences, a positive and interactive patient experience that achieves high satisfaction and a convincing value proposition for premium cataract practices and their patients."
J&J results will be viewed favorably for MedTech group, says BTIG » 11:1204/1904/19/22
JNJ, ALC, GKOS, GMED, ISRG, LNSR, NUVA, RXST, STAA, SPNE, SYK
Johnson & Johnson's (JNJ) Q1 sales in its MedTech business were better than consensus expectations and "encouraging" against a tough comp from FY21, even when accounting for an extra selling day this year that benefited results by 190 basis points, said BTIG analyst Ryan Zimmerman. The analyst, who thinks J&J's MedTech results will be viewed favorably as procedural recovery continues into Q2, also notes the company's commentary on margin pressures, raw material increases, and foreign exchanges being headwinds through the remainder of FY22. Zimmerman's MedTech coverage includes Alcon (ALC), Glaukos (GKOS), Globus Medical (GMED), Intuitive Surgical (ISRG), Lensar (LNSR), NuVasive (NUVA), RxSight (RXST), Staar Surgical (STAA), SeaSpine (SPNE) and Stryker (SYK).
RxSight initiated with a Buy at Needham » 05:4204/0804/08/22
Needham analyst David…
Needham analyst David Saxon initiated coverage of RxSight with a Buy rating and $18 price target. The RxSight System is a "differentiated" intraocular lens that can result in better visual outcomes for the patient, Saxon tells investors in a research note. The analyst believes this could drive adoption despite the incremental capital equipment required. His doctor checks suggest RxSight's intraocular lens could be appropriate for up to 20% of the cataract patient population. Saxon finds the shares attractively valued at current levels.
RxSight sees FY22 revenue $40M-$44M, consensus $38.47M » 16:2303/0803/08/22
The company said,…
The company said, "RxSight projects 2022 full year revenue to be between $40.0 million and $44.0 million, full year gross margin of 35% to 36% of revenue and full year operating expenses of $86.0 million to $90.0 million."